su011248

Breast Carcinoma

University Medical Center GroningenPhase 4 / ApprovedActive

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 81/ 100

Competitive context

65 Active assets in the Breast Carcinoma cohort.

Asset / Sponsor	Phase	Rating
TAMOXIFEN Dartmouth-Hitchcock Medical Center	Phase 4	BBB
Letrozole OHSU Knight Cancer Institute	Phase 4	BBB
Palbociclib Hongmei Zheng, PhD	Phase 4	BB
gw786034 University Medical Center Groningen	Phase 4	BB
Alisertib Mayo Clinic	Phase 2	BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.